Format

Send to

Choose Destination
Therap Adv Gastroenterol. 2012 Jul;5(4):219-32. doi: 10.1177/1756283X12437358.

Overutilization of proton-pump inhibitors: what the clinician needs to know.

Author information

1
Ypsilanti Health Center, 200 Arnet, Suite 200, Ypsilanti, MI 48198, USA.

Abstract

Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy for upper gastrointestinal disorders, including gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease. The effectiveness of PPIs has led to overutilization in multiple treatment arenas, exposing patients to an increasing number of potential risks. The overutilization of PPIs in ambulatory care settings is often a result of failure to re-evaluate the need for continuation of therapy, or insufficient use of on-demand and step-down therapy. PPI overutilization in the inpatient setting is often a result of inappropriate stress ulcer prophylaxis (SUP) in nonintensive care unit patients, and failure to discontinue SUP prior to hospital discharge. Potential consequences of prolonged PPI therapy include hypergastrinemia, enterochromaffin-like cell hyperplasia, and parietal cell hypertrophy, leading to rebound acid hypersecretion. PPIs have been linked via retrospective studies to increased risk of enteric infections including Clostridium difficile-associated diarrhea, community-acquired pneumonia, bone fracture, nutritional deficiencies, and interference with metabolism of antiplatelet agents. Reducing inappropriate prescribing of PPIs in the inpatient and outpatient settings can minimize potential for adverse events, and foster controllable cost expenditure.

KEYWORDS:

adverse risk; cost-effective; overutilization; proton-pump inhibitors; rebound acid hypersecretion

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center